Type 2 diabetes risk alleles in peptidyl-glycine alpha-amidating monooxygenase influence GLP-1 levels and response to GLP-1 receptor agonists - PubMed
9 hours ago
- #type-2-diabetes
- #GLP-1
- #pharmacogenetics
- Type 2 diabetes risk alleles in peptidyl-glycine alpha-amidating monooxygenase (PAM) affect GLP-1 levels.
- These alleles also influence the response to GLP-1 receptor agonists.
- The study involved human volunteers with ethical approval from Oxford B NRES Research Ethics Committee.
- Several authors have competing interests, including ties to pharmaceutical companies like Boehringer Ingelheim, AstraZeneca, and Novo Nordisk.
- Animal experiments were approved by the kantonale Veterinäramt Zürich.